GLP-1s are easy to get off
We only succeed when employers and their employees do, too. To mark the announcement of these new products, which will be available in January, Noom also published a whitepaper today Breaking the GLP-1 Cost Cycle: Transforming Access, Cutting Costs, and Shaping the Future of Obesity Care
RESEARCH presented at ACR Convergence 2025 highlights a potential new role for GLP-1 receptor agonists, medications widely used for type 2 diabetes and obesity, in the treatment of rheumatoid arthritis (RA)
There is no mechanistic or clinical rationale for taking breaks
Findings about the possible benefits of L-arginine are mixed, and supplements should only be considered with a doctors approval, along with a healthy diet and treatments your doctor recommends for any existing medical conditions
When a clinic sells oral compounded peptide tablets alongside injections without explaining the differences, patients are left to make medical decisions without proper context